Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cethromycin meets Phase III endpoint

Advanced Life Sciences (ADLS) said cethromycin met the primary endpoint of non-inferiority vs. Biaxin clarithromycin in clinical

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE